{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:29:08Z","timestamp":1785821348796,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OVV-152411"],"award-info":[{"award-number":["OVV-152411"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OVV-152411"],"award-info":[{"award-number":["OVV-152411"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OVV-152411"],"award-info":[{"award-number":["OVV-152411"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, tattooing technology has shown promising results toward evaluating vaccines in both animal models and humans. However, this technology has some limitations due to variability of experimental evaluations or operator procedures. The current study evaluated a device (intradermal oscillating needle array injection device: IONAID) capable of microinjecting a controlled dose of any aqueous vaccine into the intradermal space. IONAID-mediated administration of a DNA-based vaccine encoding the glycoprotein (GP) from the Ebola virus resulted in superior T- and B-cell responses with IONAID when compared to single intramuscular (IM) or intradermal (ID) injection in mice. Moreover, humoral immune responses, induced after IONAID vaccination, were significantly higher to those obtained with traditional passive DNA tattooing in guinea pigs and rabbits. This device was well tolerated and safe during HIV vaccine delivery in non-human primates (NHPs), while inducing robust immune responses. In summary, this study shows that the IONAID device improves vaccine performance, which could be beneficial to the animal and human health, and importantly, provide a dose-sparing approach (e.g., monkeypox vaccine).<\/jats:p>","DOI":"10.1038\/s41541-022-00581-y","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:02:29Z","timestamp":1671678149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-5977","authenticated-orcid":false,"given":"Alejandro M.","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Babuadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Plourde-Campagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiva","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"de La Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"XIII","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Naghibosadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Edith","family":"Nepveu-Traversy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-4943","authenticated-orcid":false,"given":"Jean","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-2298","authenticated-orcid":false,"given":"Gary P.","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/375824","volume":"37","author":"VA Fulginiti","year":"2003","unstructured":"Fulginiti, V. A. et al. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin. Infect. Dis. 37, 241\u2013250 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"581_CR2","unstructured":"Hickling, J. & Jones, R. 'Intradermal delivery of vaccines' - a review of the literature and the potential for development for use in low and middle-income countries. PATH (Program for Appropriate Technology in Health) https:\/\/www.path.org\/resources\/intradermal-delivery-of-vaccines-a-review-of-the-literature-and-the-potential-for-development-for-use-in-low-and-middle-income-countries\/ (2009)."},{"key":"581_CR3","doi-asserted-by":"crossref","unstructured":"Hettinga, J. & Carlisle, R. Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines 8, 534 (2020).","DOI":"10.3390\/vaccines8030534"},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2471\/BLT.10.079426","volume":"89","author":"JK Hickling","year":"2011","unstructured":"Hickling, J. K. et al. Intradermal delivery of vaccines: potential benefits and current challenges. Bull. World Health Organ 89, 221\u2013226 (2011).","journal-title":"Bull. World Health Organ"},{"key":"581_CR5","doi-asserted-by":"publisher","first-page":"101868","DOI":"10.1016\/j.tmaid.2020.101868","volume":"37","author":"JL Schnyder","year":"2020","unstructured":"Schnyder, J. L. et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination\u2014a systematic review and meta-analysis. Travel Med. Infect. Dis. 37, 101868 (2020).","journal-title":"Travel Med. Infect. Dis."},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1016\/j.vaccine.2008.03.095","volume":"26","author":"PH Lambert","year":"2008","unstructured":"Lambert, P. H. & Laurent, P. E. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26, 3197\u20133208 (2008).","journal-title":"Vaccine"},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2008.10.092","volume":"26","author":"V Picot","year":"2008","unstructured":"Picot, V. Intradermal immunization: an alternative route for vaccine administration. Articles as per sessions meeting report. Vaccine 26, S1\u2013S5 (2008).","journal-title":"Vaccine"},{"key":"581_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2017.01744","volume":"8","author":"ACM Platteel","year":"2017","unstructured":"Platteel, A. C. M. et al. Efficacy testing of H56 cDNA tattoo immunization against tuberculosis in a mouse model. Front. Immunol. 8, 1744 (2017).","journal-title":"Front. Immunol."},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00262-017-2006-y","volume":"66","author":"S Samuels","year":"2017","unstructured":"Samuels, S. et al. HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunol. Immunother. 66, 1163\u20131173 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/21505594.2017.1307485","volume":"8","author":"JM Lankelma","year":"2017","unstructured":"Lankelma, J. M. et al. Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application. Virulence 8, 1683\u20131694 (2017).","journal-title":"Virulence"},{"key":"581_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/gt.2014.87","volume":"21","author":"A Wagemakers","year":"2014","unstructured":"Wagemakers, A. et al. Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection. Gene Ther. 21, 1051\u20131057 (2014).","journal-title":"Gene Ther."},{"key":"581_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-6-4","volume":"6","author":"D Pokorna","year":"2008","unstructured":"Pokorna, D., Rubio, I. & Muller, M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther. 6, 4 (2008).","journal-title":"Genet Vaccines Ther."},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nm1264","volume":"11","author":"AD Bins","year":"2005","unstructured":"Bins, A. D. et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11, 899\u2013904 (2005).","journal-title":"Nat. Med."},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1016\/j.vaccine.2008.03.091","volume":"26","author":"BE Verstrepen","year":"2008","unstructured":"Verstrepen, B. E. et al. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 26, 3346\u20133351 (2008).","journal-title":"Vaccine"},{"key":"581_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.taap.2005.04.003","volume":"209","author":"NV Gopee","year":"2005","unstructured":"Gopee, N. V. et al. Response of mouse skin to tattooing: use of SKH-1 mice as a surrogate model for human tattooing. Toxicol. Appl. Pharm. 209, 145\u2013158 (2005).","journal-title":"Toxicol. Appl. Pharm."},{"key":"581_CR16","doi-asserted-by":"crossref","unstructured":"Chiu, Y. N. et al. Skin tattooing as a novel approach for DNA vaccine delivery. J. Vis. Exp. 68, e50032 (2012).","DOI":"10.3791\/50032"},{"key":"581_CR17","doi-asserted-by":"crossref","unstructured":"Fotoran, W. L. et al. A DNA vaccine encoding Plasmodium falciparum PfRH5 in cationic liposomes for dermal tattooing immunization. Vaccines 8, 619 (2020).","DOI":"10.3390\/vaccines8040619"},{"key":"581_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep04156","volume":"4","author":"MT Shio","year":"2014","unstructured":"Shio, M. T. et al. Drug delivery by tattooing to treat cutaneous leishmaniasis. Sci. Rep. 4, 4156 (2014).","journal-title":"Sci. Rep."},{"key":"581_CR19","doi-asserted-by":"crossref","unstructured":"Reynard, S. et al. Immune parameters and outcomes during Ebola virus disease. JCI Insight 4, e125106 (2019).","DOI":"10.1172\/jci.insight.125106"},{"key":"581_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","volume":"25","author":"SA Ehrhardt","year":"2019","unstructured":"Ehrhardt, S. A. et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nat. Med. 25, 1589\u20131600 (2019).","journal-title":"Nat. Med."},{"key":"581_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/infdis\/jiy565","volume":"219","author":"JH Poetsch","year":"2019","unstructured":"Poetsch, J. H. et al. Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J. Infect. Dis. 219, 556\u2013561 (2019).","journal-title":"J. Infect. Dis."},{"key":"581_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Wang, W. & Wang, S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev. Vaccines 14, 1509\u20131523 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"581_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12249-019-1564-z","volume":"21","author":"C Chang","year":"2019","unstructured":"Chang, C. et al. Stable immune response induced by intradermal DNA vaccination by a novel needleless Pyro-Drive Jet Injector. AAPS PharmSciTech 21, 19 (2019).","journal-title":"AAPS PharmSciTech"},{"key":"581_CR24","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1016\/j.vaccine.2019.06.083","volume":"37","author":"M Williams","year":"2019","unstructured":"Williams, M. et al. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery. Vaccine 37, 4444\u20134453 (2019).","journal-title":"Vaccine"},{"key":"581_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/infdis\/jiz132","volume":"220","author":"P Tebas","year":"2019","unstructured":"Tebas, P. et al. Intradermal SynCon(R) Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. J. Infect. Dis. 220, 400\u2013410 (2019).","journal-title":"J. Infect. Dis."},{"key":"581_CR26","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1016\/j.vaccine.2010.03.034","volume":"28","author":"A Endmann","year":"2010","unstructured":"Endmann, A. et al. Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 28, 3642\u20133649 (2010).","journal-title":"Vaccine"},{"key":"581_CR27","doi-asserted-by":"crossref","unstructured":"Louis, L. et al. Intradermal synthetic DNA vaccination generates leishmania-specific T cells in the skin and protection against Leishmania major. Infect Immun. 87, e00227-19 (2019).","DOI":"10.1128\/IAI.00227-19"},{"key":"581_CR28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.vaccine.2018.11.041","volume":"37","author":"W Hegazy-Hassan","year":"2019","unstructured":"Hegazy-Hassan, W. et al. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice. Vaccine 37, 248\u2013257 (2019).","journal-title":"Vaccine"},{"key":"581_CR29","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2009.03.001","volume":"27","author":"A Potthoff","year":"2009","unstructured":"Potthoff, A. et al. Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine 27, 2768\u20132774 (2009).","journal-title":"Vaccine"},{"key":"581_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/jid.2008.225","volume":"129","author":"LC Zaba","year":"2009","unstructured":"Zaba, L. C., Krueger, J. G. & Lowes, M. A. Resident and \u201cinflammatory\u201d dendritic cells in human skin. J. Invest. Dermatol. 129, 302\u2013308 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"581_CR31","first-page":"221","volume":"351","author":"K Oosterhuis","year":"2012","unstructured":"Oosterhuis, K. et al. DNA vaccines and intradermal vaccination by DNA tattooing. Curr. Top. Microbiol Immunol. 351, 221\u2013250 (2012).","journal-title":"Curr. Top. Microbiol Immunol."},{"key":"581_CR32","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1128\/JVI.00185-14","volume":"88","author":"AD Rice","year":"2014","unstructured":"Rice, A. D. et al. Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease. J. Virol. 88, 7753\u20137763 (2014).","journal-title":"J. Virol."},{"key":"581_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/hum.2008.073","volume":"20","author":"JH van den Berg","year":"2009","unstructured":"van den Berg, J. H. et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum. Gene Ther. 20, 181\u2013189 (2009).","journal-title":"Hum. Gene Ther."},{"key":"581_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00461-5","volume":"7","author":"GG Babuadze","year":"2022","unstructured":"Babuadze, G. G. et al. Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. NPJ Vaccines 7, 49 (2022).","journal-title":"NPJ Vaccines"},{"key":"581_CR35","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1016\/j.vaccine.2010.12.057","volume":"29","author":"F Lin","year":"2011","unstructured":"Lin, F. et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29, 6771\u20136780 (2011).","journal-title":"Vaccine"},{"key":"581_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad, K. et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect. Dis. 19, 1013\u20131022 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"581_CR37","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.celrep.2018.10.062","volume":"25","author":"A Patel","year":"2018","unstructured":"Patel, A. et al. In vivo delivery of synthetic human DNA-Encoded monoclonal antibodies protect against Ebolavirus infection in a mouse model. Cell Rep. 25, 1982\u20131993 (2018).","journal-title":"Cell Rep."},{"key":"581_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/infdis\/jiy537","volume":"219","author":"A Patel","year":"2019","unstructured":"Patel, A. et al. Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines. J. Infect. Dis. 219, 544\u2013555 (2019).","journal-title":"J. Infect. Dis."},{"key":"581_CR39","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1099\/vir.0.81989-0","volume":"87","author":"S Roy","year":"2006","unstructured":"Roy, S. et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J. Gen. Virol. 87, 2477\u20132485 (2006).","journal-title":"J. Gen. Virol."},{"key":"581_CR40","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1016\/j.vaccine.2021.10.008","volume":"39","author":"GG Babuadze","year":"2021","unstructured":"Babuadze, G. G. et al. A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. Vaccine 39, 7175\u20137181 (2021).","journal-title":"Vaccine"},{"key":"581_CR41","doi-asserted-by":"publisher","first-page":"7949","DOI":"10.1016\/j.vaccine.2020.10.058","volume":"38","author":"M Mangion","year":"2020","unstructured":"Mangion, M. et al. Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. Vaccine 38, 7949\u20137955 (2020).","journal-title":"Vaccine"},{"key":"581_CR42","first-page":"1025","volume":"41","author":"RA Pennie","year":"1995","unstructured":"Pennie, R. A. Mantoux tests. Performing, interpreting, and acting upon them. Can. Fam. Physician 41, 1025\u20131029 (1995).","journal-title":"Can. Fam. Physician"},{"key":"581_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"581_CR44","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3201\/eid2609.201495","volume":"26","author":"A Banerjee","year":"2020","unstructured":"Banerjee, A. et al. Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 2054\u20132063 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"581_CR45","doi-asserted-by":"crossref","unstructured":"Abe, K. T. et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 5, e142362 (2020).","DOI":"10.1172\/jci.insight.142362"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00581-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T03:02:52Z","timestamp":1671678172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00581-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors A.M.G., G.B., M-A.P.C., H.A., A.B., R.K., M.A.D.L.V., A.X., M.N., M-E.N.T. and J.R. declare no competing interests. The authors have no financial conflicts of interest at the time these studies were conducted and this manuscript written. As of August 2022, Gary Kobinger has agreed to be the technical advisor on the commercial development of IONAID to a start-up company registered in Canada in which he owns equity. The company (Inocujet Inc.) has no monetary value at the time of submission.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}